Cardiology Pharmaceuticals July 31, 2023
Lilly Shows Tirzepatide Superiority in SURMOUNT-3 and 4 July 31, 2023
Results from Eli Lilly’s SURMOUNT-3 and SURMOUNT-4 trials are in, and they confirmed that its GLP-1 / GIP agonist tirzepatide (aka Mounjaro) drives significant weight loss among obese or overweight adults who don’t have type 2 diabetes.
Cardiology Pharmaceuticals July 27, 2023
Alnylam and Roche’s Long-Lasting Antihypertensive Alliance July 27, 2023
Just days after Alnylam Pharmaceuticals showed that a single injection of zilebesiran can control blood pressure for up to six months, the biotech has joined forces with Roche to usher the mid-stage medication through its clinical trials into clinical use.
Cardiology Pharmaceuticals July 24, 2023
Zilebesiran’s Long-Lasting Antihypertensive Potential July 24, 2023
Could the first long-lasting antihypertensive medication be on the way? Results of a Phase 1 study in NEJM suggests that Alnylam Pharmaceuticals’ zilebesiran is a frontrunner to become that drug, showing that a single injection controls blood pressure for up to six months.
Digital Health July 20, 2023
Astellas Expands into Heart Failure Digital Therapeutics July 20, 2023
Astellas Pharma and Eko Health announced an alliance that will make Eko's digital stethoscope and CVD detection software and Welldoc’s chronic care management capabilities the core components of Astellas’ new Z1608 digital therapeutic for heart failure.
Cardiology Pharmaceuticals July 17, 2023
Lilly Diversifies Weight Loss Pipeline with Versanis Acquisition July 17, 2023
Eli Lilly bolstered its already strong position in the white hot obesity drug segment, acquiring cardiometabolic disease biopharma startup Versanis for up to $1.92 billion.
Cardiology Pharmaceuticals July 13, 2023
Cholesterol Control Falls Short in CAD Patients July 13, 2023
For years we’ve known that controlling LDL cholesterol lowers the risk of future cardiovascular events in people with coronary artery disease. And yet, a new JAMA paper reveals that most CAD patients fail to meet recommended cholesterol targets, and many of them still aren't taking LDL-lowering medications.
Surgeries & Interventions July 10, 2023
The First Dissolvable Heart Monitor and Pacer July 10, 2023
A team of Northwestern and George Washington scientists took a big step towards revolutionizing how patients are monitored and treated after major cardiac events, unveiling the first dissolvable cardiac mapping and pacing device.
Artificial Intelligence July 6, 2023
Improving Occlusion MI Detection with ECG AI July 6, 2023
A University of Pittsburgh-led team developed an ECG-based AI model capable of detecting occlusion myocardial infarction, showing that it improves both OMI detection and assessments, and finding that it has real clinical potential.
Cardiology Pharmaceuticals June 29, 2023
Two Sides to Bempedoic Acid’s Primary Prevention Impact June 29, 2023
A Cleveland Clinic-led study stunned the ADA 2023 crowd this week, showing that bempedoic acid (Esperion’s Nexletol) significantly reduced future cardiovascular events among people with high CVD risks who had never experienced a major cardiac event.
Surgeries & Interventions June 26, 2023
How to Assess the Abiomed Impella Pump June 26, 2023
Abiomed’s Impella pump is being used across America to support patients with acute myocardial infarction with cardiogenic shock (AMICS) - but do we know it’s safe and effective?
Cardiology Pharmaceuticals June 22, 2023
Agepha’s Lodoco FDA-Approved for CVD Inflammation June 22, 2023
Agepha Pharma’s Lodoco (colchicine) just became the first anti-inflammatory drug to land FDA approval for reducing cardiovascular event risks, marking a major milestone in the emerging field of CVD inflammation treatment.
Cardiology Pharmaceuticals June 20, 2023
NYU’s Atherosclerosis Inflammation Discovery June 20, 2023
NYU researchers discovered that AstraZeneca’s saracatinib - an investigational drug originally developed to treat cancer - could slow atherosclerosis progression by addressing inflammation that we know contributes to ASCVD and haven't figured out how to treat.
Cardiology Policy June 15, 2023
Glenfield Hospital’s Nurse-Performed TAVI Uproar June 15, 2023
Glenfield Hospital Cardiology, just outside Leicester in the UK, set cardiology channels ablaze earlier this week with a celebratory tweet announcing that one of its advanced nurse practitioners performed a whole TAVI procedure (aka TAVR in the U.S.) as the first operator.
Cardiology Pharmaceuticals June 12, 2023
Bitterroot Bio’s Cardio-Immunology Mission June 12, 2023
Bitterroot Bio emerged last week, announcing a massive $145M Series A round and an equally massive mission to “rewrite the practice of cardiology” through cardio-immunology therapeutics.
Cardiology Guidelines June 8, 2023
Questioning Antihypertensives for Older Patients June 8, 2023
When clinicians find that an older hospitalized patient has elevated blood pressure, their next step is often to initiate antihypertensive treatment, but a new JAMA Internal Medicine study suggests that many of these patients would be better off having their BPs left unmanaged.
Cardiology Pharmaceuticals June 5, 2023
Lexicon’s Lands Long-Awaited HF Approval June 5, 2023
Lexicon Pharmaceuticals’ Inpefa (sotagliflozin) just became the first FDA-approved dual SGLT2 / SGLT1 inhibitor for treating heart failure, landing a wide-ranging approval that could alter the HF treatment arena.
Remote Care June 1, 2023
UCSD’s Wearable Cardiac Ultrasound Milestone June 1, 2023
A team of UCSD scientists took a major step towards changing how, when, and where cardiac ultrasound exams are performed, unveiling the first fully integrated wearable ultrasound system intended for continuous heart monitoring.
Remote Care May 25, 2023
Remote Cardiac Monitoring Gains Momentum May 25, 2023
The last week featured two of the world’s largest heart failure and electrophysiology conferences, each driving a surge of new papers and studies suggesting that remote monitoring is moving to the forefront of both cardiology subspecialties.
Cardiology Pharmaceuticals May 22, 2023
SCOTUS Rules Against Amgen in PCSK9 Patent Dispute May 22, 2023
The U.S. Supreme Court ruled against Amgen in its PCSK9 inhibitor patent dispute with Sanofi and Regeneron that was intended to revive patents for Amgen’s cholesterol-lowering drug, Repatha.
